Role of posaconazole in the management of oropharyngeal and esophageal candidiasis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 4, 2007, Pages 533-542

  Vazquez, Jose A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV infected; Oropharyngeal and esophageal candidiasis; Posaconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTACID AGENT; ANTIRETROVIRUS AGENT; ASTEMIZOLE; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CLOTRIMAZOLE; CRYSTAL VIOLET; CYCLOSPORIN; ECHINOCANDIN; ERGOT ALKALOID; FLUCONAZOLE; HALOFANTRINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MIDAZOLAM; NYSTATIN; PHENYTOIN; PIMOZIDE; PLACEBO; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; QUINIDINE; RIFABUTIN; TACROLIMUS; TERFENADINE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; CANDIDA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUTION; DRUG STRUCTURE; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; ECG ABNORMALITY; ESOPHAGUS CANDIDIASIS; FLATULENCE; FLUSHING; FUNGAL STRAIN; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; PARESTHESIA; PATIENT COMPLIANCE; QT PROLONGATION; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYMPTOMATOLOGY; TABLET FORMULATION; TASTE DISORDER; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

EID: 34848918840     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Albengres E, Le Louet H, Tillement JP. 1998. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf, 18:83-97.
2. Ally R, Schurmann D, Kreisel W, et al. 2001. A randomized double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis, 33:1447-54.
3. Barchiesi F, Morbiducci V, Ancarani F, et al. 1993. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol, 9:455-56.
4. Barone JA, Moskovitz BL Guarnieri J, et al. 1998. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution compared with capsules in healthy volunteers. Antimicrob Agents Chemother, 42:1862-65.
5. Chau AS, Mendrick CA, Sabatelli FJ, et al. 2004. Application of real-time quantitive PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother, 48:2124-31.
6. Coker RJ, Fisher M, Tomlinson DR. 1995. Management of mycoses associated with HIV disease. Int J STD AIDS, 6:408-12.
7. Como JA, Dismukes WE. 1994. Oral azole drugs as systemic antifungal therapy. N Engl J Med, 330:263-72.
8. Como J, Dismukes WE. 2003. Azole antifungal drugs. In Dismukes WE, Pappas PG, Sobel JD (eds). Clinical Mycology. 1st ed. New York, NY: Oxford University Press. p 64-87.
9. Courtney R, Laughlin M, Gontz H, et al. 2000b. Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease. Annual Meeting of American Association of Pharmaceutical Scientists; October 29-November 2. Indianapolis, IN.
10. Courtney R, Martinho M, Lim J, et al. 2000a. Evaluation of the effect of age, weights, race, and gender on posaconazole plasma concentrations in HIV-infected patients. 3rd European Congress of Clinical Microbiology and Infectious Diseases; May 10-13. Glasgow, Scotland.
11. Courtney R, Pai S, Laughlin M, et al. 2003b. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother, 47:2788-95.
12. Courtney R, Sansone A, Calzetta A, et al. 2003c. The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17. Chicago, IL.
13. Courtney R, Sansone A, Kantesaria B, et al. 2003d. Effect of ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17. Chicago, IL: 2003.
14. Courtney R, Sansone A, Radwanski E, et al. 2003a. Relative oral bioavailability of three formulations of posaconazole in healthy volunteers: basis for clinical development of the suspension. 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13. Glasgow, Scotland.
15. Courtney R. Sansone A, Statkevich P, et al. 2003e. Effect of age and gender on the pharmacokinetics of posaconazole in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17. Chicago, IL.
16. Courtney R, Sansone A, Statkavich P, et al. 2003f. Pharmacokinetics of posaconazole in subjects with varying degrees of renal insufficiency. 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13. Glasgow, Scotland.
17. Courtney R, Wexler D, Radwanski E, et al. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol, 57:218-22.
18. Darouiche RO. 1998. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis, 26:259-74.
19. DeWit S, Weerts D, Goossens H, et al. 1989. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet, 1:746-8.
20. Dupont B, Denning DW, Marriot D, et al. 1994. Mycosis in AIDS. J Med Vet Mycology, (Suppl)32:65-77.
21. Ezzet F, Wexler D, Courtney R, et al. 2007. The oral bioavailability of posaconazole in fasted healthy subjects: basis for clinical dosage recommendations. Clin Pharmacokinet. In press.
22. Graybill JR, Vazquez J, Darouiche RO, et al. 1998. Itraconazole oral solution: a novel and effective treatment for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med, 104:33-9.
23. Groll AH, Walsh TG. 2003. Cell wall synthesis inhibitors: echinocandins and nikkomycins. In Dismukes WE, Pappas PG, Sobel JD (eds). Clinical Mycology. 1st ed. New York, NY: Oxford University Press. p88-103.
24. Hay RJ. 1990. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis, 12(Suppl 3):S334-7.
25. Heimark L, Shipkova P, Greene J, et al. 2002. Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J Mass Specgrom, 37:265-9.
26. Herbrecht R. 2004. Posaconazole: a potent extended spectrum triazole antifungal for the treatment of serious fungal infections. Int J Clin Pract, 58:612-24.
27. Hippocrates CA, Adams F. 1939. Epidemics, Book 3. Baltimore: Williams and Wilkins.
28. Honig PK, Wortham DC, Zamani K, et al. 1993. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 269:1513-8.
29. Hostetler JS, Hanson LH, Stevens DA. 1992. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother, 36:477-80.
30. Hughes WT, Bartley DL, Patterson GG, et al. 1983. Ketoconazole and candidiasis: a controlled study. J Infect Dis, 147:1060-3.
31. Imam N, Carpenter CC, Mayer KH, Fisher A, Stein M, Danforth SB. 1990. Hierarchical pattern of mucosal candida infections in HIV-seropositive women. Am J Med, 89:142-6.
32. Jensen KB, Stenderup A, Thomsen JB. 1964. Esophageal moniliasis in malignant neoplastic disease. Acta Med Scand, 175:455-9.
33. Johnston RD, Chick EW, Johnston NS, et al. 1967. Asymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing conditions. South Med J, 60:1244-7.
34. Koletar SL, Russell JA, Fass RJ, et al. 1990. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother, 34:2267-8.
35. Kowalsky SF, Dixon DM. 1991. Fluconazole: a new antifungal agent. Clin Pharm, 10:179-94.
36. Kozinin PJ, Taschdjian CL, Dragutsky D, et al. 1957. Therapy of oral thrush: a comparative evaluation of gentian violet, mycostatin and amphotericin B. Monogr Ther, 2:16-24.
37. 14C posaconazole following oral administration in healthy male subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30. San Diego, CA.
38. Li X, Brown, Chau AS, et al. 2004. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicorb Chemother, 53:74-80.
39. McCarthy GM, Mackie ID, Koval J, et al. 1991. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med, 20:332-6.
40. Maenza JR, Keruly JC, Moore RD, et al. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis, 173:219-25.
41. Meunier F, Aoun M, Gerard M. 1990. Therapy of oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Rev Infect Dis, 12(Suppl 3):S364-8.
42. Meyer JM, Rodvold KA. 1996. Drug biotransformation by the cytochrome P-450 enzyme system. Infect Med, June:452-4.
43. Moore RD, Chaisson RE. 1996. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med, 124:633-42.
44. Munayyer HK, Mann PA, Chau AS et al. 2004. Posaconazole is a potent inhibitor of sterol 14 alpha demethylation in yeasts and molds. Antimicrob Agents Chemother, 48:3690.
45. Murray PA, Koletar SL, Mallegol I, et al. 1997. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther, 19:471-80.
46. Odds FC. 1988. Candida and Candidosis. A review and bibliography. London: Baillière Tindall.
47. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United states. Antimicrob Agents Chemother, 47:3149-54.
48. Pappas PG, Rex JH, Sobel JD, et al. 2004. Guidelines for treatment of candidiasis. Clin Infect Dis, 38:161-89.
49. Pfizer, Inc. 2003. Package insert. NY, New York.
50. Piscitelli, SC, Flexner C, Minor JR, et al. 1996. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis, 23:685-93.
51. Pitisuttithum P, Gaona-Flores V, Negroni R, et al. 2003. Efficacy of posaconazole in treatment of central nervous system fungal infections: results of an open-label study. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17. Chicago, IL.
52. Pons V, Greenspan D, Debruin M, et al. 1993. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multi-center study of oral fluconazole versus clotrimazole troches. J Acquir Immune Defic Syndr, 6:1311-6.
53. Pons V, Greenspan D, Lozada-Nur F, et al. 1997. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis, 24:1204-7.
54. Quintiliani R, Owens NJ, Quercia RA, et al. 1994. Treatment and prevention of oropharyngeal candidiasis. Am J Med, 77(Suppl 4D):44-8.
55. Raad II, Hachem RY, Herbrecht R, et al. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis, 42:1398.
56. Reef SE, Mayer KH. 1995. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis, 21 (Suppl 1):S99-102.
57. Sabatelli FJ, Patel R, Mann PA, et al. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Approximately 18,000 strains of clinically significant yeasts and moulds. Antimicrob Agents Chemother, 50:2009.
58. Schering Corporation. 2006. Package insert. Kenilworth, NJ.
59. Scott BB, Jenkins D. 1982. Gastro-oesophageal candidiasis. Gut, 23:137-9.
60. Shectman LB, Funaro L, Robin T, et al. 1984. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med, 76:91-4.
61. Silverman S Jr, Gallo JW, McKnight ML, et al. 1996. Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 82:402-7.
62. Skiest DJ, Vazquez JA, Anstead GM, et al. 2006. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV-infection. Clin Infect Dis. In press.
63. Tucker RM, Denning DW, Hanson LH, et al. 1992. Interactions of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis, 14:165-74.
64. Ullmann AJ, Cornely OA, Burchard T, et al. 2005. Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogenic hematopoietic stem cell transplant recipients with graft-versus-host disease. Poster presented at the 46th Interscience Conference on Antimicrob Agents Chemother.
65. van Burik JA, Hare RS, Solomon F, et al. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of91 cases. Clin Infect Dis, 42:e61.
66. Van de Velde VJS, Van Peer AP, Heykants JJP, et al. 1996. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy, 16:424-8.
67. van't Wout JW. 1996. Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis, 15:238-42.
68. Vazquez JA, Sobel JD. 1997. Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host [abstract]. Excerpta Medica, Abstract 1-11.
69. Vazquez JA. 1999. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy, 19:76-87.
70. Vazquez JA, Sobel JD. 2003. Candidiasis. In Dismukes WE, Pappas PG, Sobel JD (eds). Clinical Mycology. 1st ed. New York, NY: Oxford University Press. p 143-87.
71. Vazquez JA, Skiest DJ, Nieto L, et al. 2006. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis, 42:1179-86.
72. Vazquez JA, Skiest DJ, Tissot-Dupont H, et al. 2007. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. HIV Clin Trials. In press.
73. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. 2000. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet, 38:111-80.
74. Wexler D, Laughlin M, Courtney R, et al. 2004. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci, 21:645.
75. Wilcox CM, Darouiche RO, Lame L, et al. 1997. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis, 176:227-32.
76. Xiao L, Madison C, Chaui AS, et al. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14 alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother, 48:568-74.